GlaxoSmithKline (GSK) Shingles Vaccine News a Win for Agenus (AGEN), Maxim Group Says; PT to $10
Get Alerts AGEN Hot Sheet
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 13 | Down: 10 | New: 11
Join SI Premium – FREE
Maxim Group analyst Jason Kolbert reiterated a Buy rating and bumped his price target on Agenus Inc. (NASDAQ: AGEN) to $10.00 (from $9.00) after GlaxoSmithKline (NYSE: GSK) reported that its shingles vaccine, HZ/su, which incorporates Agenus' QS-21 adjuvent, produced a reduction in the risk of shingles by more than 97% in a long-term (four-year), 16,000-patient pivotal study (ZOE-50).
Kolbert commented, "This is a win for Agenus and QS-21. The adjuvant works in the shingles vaccine, a $750M market in which Agenus will likely be entitled to single-digit royalties from GSK. As such, we have modeled a 7% royalty to Agenus from GSK, which results in an increase in our 2015 price target from $9.00 to $10.00."
For an analyst ratings summary and ratings history on Agenus Inc. click here. For more ratings news on Agenus Inc. click here.
Shares of Agenus Inc. closed at $3.93 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hennes & Mauritz AB (HMB:SS) (HNNMY) PT Raised to SEK190 at RBC Capital, 'showing some promising signs '
- Hyundai Motor (005380:KS) (HYMTF) PT Raised to KRW290 at Citi
- AO World Plc. (AO/:LN) PT Raised to GBP1.25 at Jefferies
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, FDARelated Entities
Maxim GroupSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!